relx.com

For the first time in its 15-year history, the RELX Environmental Challenge has expanded with a new Ocean category, recognising the critical role of healthy oceans and marine ecosystems in environmental sustainability and resilience. Following more than 100 applications from around the world, five innovative projects have been selected for the inaugural Ocean shortlist.

The Open for Business City Ratings benchmarks 149 cities based on their performance across two key dimensions: LGBTQ+ inclusion and economic competitiveness. First launched in 2018 and updated in 2020 and 2022, this fourth edition delivers fresh insights and consolidated data points. Explore the 2025 City Ratings to see how your city ranks and what makes these urban hubs the powerhouses of innovation and progress.

Building a Sustainable Future Through Purpose-Driven Leadership In this episode of the "World We Want" podcast, Márcia Balisciano interviews Isabelle Grosmaitre, Founder & CEO, Goodness & Co. They discuss how purpose-driven leadership can help businesses create long-term value through sustainable strategy, collaborative governance, and responsible decision-making.

Since launching in 2011, the RELX Environmental Challenge has awarded over US$1.2 million to more than 30 projects across 25+ countries, advancing solutions that improve access to safe water and sanitation. Innovation has ranged from low-cost water purification and sanitation technologies to circular waste-to-resource systems, nature-based solutions, and data-enabled systems, helping innovators move from idea to impact and scale.

Alzheimer's disease (AD) is progressive neurodegenerative disorder whose treatment is limited by the poor brain delivery of therapeutic agents to cross blood-brain barrier. Herein, we developed nose-to-brain drug delivery system via microneedle-mediated delivery of donepezil (DPZ)-loaded engineered extracellular vesicles (EVs) for enhanced treatment of AD.

Dementia and cognitive impairment due to Alzheimer's disease (AD), are common in the elderly population worldwide. Diagnosis of AD is based on clinical evaluation, neuropsychological assessment tools, biomarkers and imaging modalities such as brain Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) scan. Since anti-amyloid monoclonal antibodies for AD have been recently introduced, early diagnosis is essential for timely treatment initiation.

Introduction: Subjective Cognitive Decline (SCD) is an early indicator of Alzheimer’s disease (AD), and accurate identification of high-risk individuals is essential for timely intervention. Predicting the progression of SCD remains challenging, particularly in resource-limited clinical settings where advanced neuroimaging is not routinely available.

Auditory agnosia for environmental sounds is a type of agnosia attributed to central auditory dysfunction. It is common in Alzheimer’s disease, and is associated with peripheral hearing loss, although independent of it, and presumed independent of language deficits. The effects of this type of agnosia on daily life in Alzheimer’s disease are unknown.

Early-phase Aβ imaging can detect cerebral perfusion deficits, while glymphatic dysfunction is a key event in neurodegenerative diseases, including Alzheimer's disease (AD). However, their relationship within the AD continuum remains unclear.

The microorganisms residing the oral cavity, referred to as the oral microbiome, have been reported to have an association with health and disease in older adults. In the present review the state-of-the-art methodology was applied to investigate the association of the oral microbiome to systemic diseases, frailty and ageing.